Finvest
PLXS Electronic manufacturing services · EMS · Regulated markets · Defense · Thesis updated June 14, 2026

Plexus recovery is real, cash is the test

01 Running thesis

Growth came back, cash has not

Plexus now looks much healthier than it did after Q1. The weak spot then was Industrial, which had shrunk 3.7% year over year. In Q2 fiscal 2026, that same sector grew 20.6%. Aerospace/Defense grew 23.0%, and Healthcare/Life Sciences grew 15.1%. That makes the recovery broad, not narrow.

Profit also improved. Operating margin reached 5.3% in Q2 fiscal 2026. That matters because Plexus is a services and manufacturing partner, so small margin gains can add up when revenue is rising across several end markets.

The main question has moved from demand to cash. Operating cash flow was only $13.1 million for the first six months of fiscal 2026, down from $90.3 million in the prior year period. Management tied this to a $170.7 million inventory increase for program ramps. If that inventory turns into shipments, the bull case gets stronger. If it sits too long, profit may not turn into free cash flow.

Finn's overall view is balanced. The business is improving, but the score is not a victory lap. The stock still needs proof that growth can last, margins can hold near Q2 levels, and cash flow can catch up.

May 2026Q2 fiscal 2026 showed a broad recovery. Industrial moved from a 3.7% Q1 decline to 20.6% growth, while all three market sectors grew at double-digit rates and operating margin reached 5.3%.
Feb 2026Q1 fiscal 2026 reduced the fear of a slow recovery, with Healthcare/Life Sciences up 24.6% and Aerospace/Defense up 11.5%. Industrial still fell 3.7%, and the company guided to a fiscal 2026 effective tax rate of about 16.0% to 18.0%.
Nov 2025Fiscal 2025 net sales grew only 1.8%, which cooled the recovery story. The 10-K also added a clearer global minimum tax risk tied to tax holidays and future effective tax rates.
Aug 2025Q3 fiscal 2025 improved the demand picture. Industrial returned to 2.9% growth, Healthcare/Life Sciences grew 10.6%, and Aerospace/Defense grew 3.2%.
May 2025Q2 fiscal 2025 showed recovery in two of three markets, with Healthcare/Life Sciences up 8.5% and Aerospace/Defense up 1.3%. Industrial fell 5.1%, making that segment the main new concern.
Jan 2025Q1 fiscal 2025 showed mixed demand but better profitability. Industrial grew 1.8%, Healthcare/Life Sciences fell 1.8%, Aerospace/Defense fell 4.4%, and gross margin improved to 10.3%.
Nov 2024The initial view framed Plexus as a specialized electronics manufacturing partner. Fiscal 2024 revenue fell 5.9%, as Aerospace/Defense strength was offset by weakness in larger Healthcare/Life Sciences and Industrial markets.
02 Business model

Complex products for picky customers

Plexus does not sell its own branded products. It helps other companies design, source parts for, launch, build, and support complex electronics. Its customers are in markets where mistakes can be costly, such as medical devices, defense systems, industrial automation, and semiconductor equipment.

The company works in two main ways. In a turnkey job, Plexus buys the parts and delivers the finished product. In a consignment job, the customer supplies some or all of the parts. Turnkey work can create more revenue, but it also ties up cash in inventory.

The strategy is not to chase the highest volume consumer gadgets. Plexus aims for harder, lower-volume products with strict rules and long customer relationships. Its financial goal is a 15% return on invested capital, meaning profit compared with the money tied up in plants, inventory, and other assets.

That model breaks when demand shifts quickly or parts are hard to get. It also breaks if customers do not give long-term purchase commitments, because Plexus may still need to hire people and buy materials before orders fully arrive.

03 Product portfolio

Services, not house brands

Option

Design & Development

Plexus helps customers turn ideas into manufacturable products. This can pull the company into programs earlier and make later production work more likely.

Steady

Supply Chain Solutions

The company sources parts and manages suppliers for complex products. This is useful for customers, but it can consume cash when inventory rises ahead of sales.

Growth engine

New Product Introduction

Plexus helps move new products from prototype to production. Recent revenue growth includes production ramps for new customers and new products.

Cash cow

Manufacturing

Manufacturing is the core work: building complex products for regulated markets. Scale and good factory use can help margins when demand improves.

Steady

Sustaining Services

Plexus supports products after launch, helping keep them in the market longer. This can be steadier than one-time launch work.

04 Business segments

Three markets now growing

Industrial41%growing fast
Healthcare/Life Sciences41%growing fast
Aerospace/Defense18%growing fast

Mix is based on Q2 fiscal 2026 net sales by market sector. Plexus reports formal segments by geography, but manages its market strategy around Industrial, Healthcare/Life Sciences, and Aerospace/Defense.

05 Risk factors

What could still go wrong

Inventory does not turn into cash

High impact · Medium odds

The biggest near-term risk is working capital. First-half fiscal 2026 operating cash flow was $13.1 million, far below $90.3 million in the prior year period. Management said inventory rose by $170.7 million to support program ramps. If those ramps slip, cash flow could stay weak even while reported profit looks good.

We watchOperating cash flow, inventory balance, and management comments on ramp timing in the second half of fiscal 2026.

Industrial growth fades again

Medium impact · Medium odds

Industrial was the key swing factor. It moved from a 3.7% decline in Q1 fiscal 2026 to 20.6% growth in Q2 fiscal 2026. Some of that growth came from new customer and product ramps. If those were one-time boosts or easy comparisons, the recovery could look less broad later.

We watchIndustrial year-over-year revenue growth and whether management cites repeatable end-market demand rather than only ramps.

Customer concentration cuts both ways

High impact · Medium odds

The top 10 customers were 49.1% of fiscal 2025 net sales. Plexus also says customers generally do not give long-term purchase commitments. A lost program, delayed order, or customer inventory correction can hit factories and margins quickly.

We watchTop customer concentration, major program wins or losses, and signs of customer order delays.

Global minimum tax lowers earnings power

Medium impact · High odds

Plexus has benefited from tax holidays, including in Malaysia. Management warned that global minimum tax rules are expected to materially and unfavorably affect those benefits and the effective tax rate. For fiscal 2026, the company expected an annual effective tax rate of about 16.0% to 18.0%, assuming no tax law changes.

We watchEffective tax rate guidance, updates on Malaysian tax holidays, and any change in global minimum tax rules.

Regulated products raise the cost of mistakes

Medium impact · Low odds

Plexus serves Healthcare/Life Sciences and Aerospace/Defense customers, where product quality and rules matter a lot. A manufacturing defect, audit issue, or compliance failure could damage customer trust and delay production. These markets can be attractive, but the bar is high.

We watchRegulatory disclosures, quality issues, recalls, customer audits, and delays tied to compliance.
06 Quick answers

In one breath

What does Plexus Corp. do?

Plexus helps other companies design, source, launch, manufacture, and support complex electronics. It focuses on regulated and high-complexity markets such as Industrial, Healthcare/Life Sciences, and Aerospace/Defense.

Does Plexus sell its own products?

No. Plexus is mainly a product lifecycle and manufacturing partner. Its value comes from helping customers build difficult products, not from selling a Plexus-branded device.

Why is cash flow the key issue for PLXS?

Revenue and margins improved in Q2 fiscal 2026, but operating cash flow for the first half was only $13.1 million. The company built inventory for program ramps, so investors need to see that inventory convert into shipments and cash.

What are Plexus's main end markets?

In Q2 fiscal 2026, Industrial was 41.1% of sales, Healthcare/Life Sciences was 40.6%, and Aerospace/Defense was 18.2%. All three grew at double-digit rates that quarter.